Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Johns Hopkins University cancer researcher Mikala Egeblad has received the 2025 Ernst W. Bertner Memorial Award in ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...

Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...

Brazilian researchers have found that stellate pancreatic cells produce periostin, which reshapes surrounding tissue and allows tumors to spread more easily, helping explain why the disease is so ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...